.jpg)
Ono licenses rare blood disease drug from Ionis for $280M upfront
Ono Pharmaceuticals is spending $280 million upfront to take the global rights of Ionis Pharmaceuticals’ asset for a rare blood disorder, marking the latest partnership for a disease space that has seen traction in recent ...
Ono Pharmaceuticals is spending $280 million upfront to take the global rights of Ionis Pharmaceuticals’ asset for a rare blood disorder, marking the latest partnership for a disease space that has seen traction in recent ...
